Computationally designed broad coronavirus vaccine is safe and immunogenic in first human trial
A Phase 1 trial in 39 volunteers found that a vaccine antigen designed entirely by computer (Cambridge / DIOSynVax, Jonathan Heeney) was safe and raised immune responses against SARS-CoV-2, SARS and bat coronaviruses. It was reported as the first time a vaccine whose active ingredient was created entirely through computer simulations was tested in people.
Key facts
- Phase 1, 39 volunteers; Journal of Infection (2026)
- Broad responses against SARS-CoV-2, SARS-CoV-1 and bat sarbecoviruses
- Design used computational structure-based antigen design and ML; exact AI contribution less specific than headlines suggest
Science result
- Field
- medicine / vaccinology
- Problem
- Broadly protective vaccines against current and future coronaviruses
- Result
- A computationally designed pan-sarbecovirus antigen was safe and broadly immunogenic in humans.
- AI system
- DIOSynVax computational antigen design platform
- Human role
- Human-led with computational/AI tools
- Verification
- Phase 1 clinical trial; peer-reviewed
- Status
- confirmed
What happened
An antigen engineered in silico to present conserved coronavirus epitopes completed a first-in-human trial.
Why it matters
It is an early human validation of computer-designed vaccine antigens, relevant to pandemic preparedness.
Changelog
- 2026-09-29: created
Related events
Sources (2)
id: 2026-06-05-ai-designed-coronavirus-vaccine-trial · updated 2026-09-29 · open in the interactive timeline